Saccharomyces boulardii (CNCM I-745): Evidence Review

What makes Saccharomyces boulardii distinct

Saccharomyces boulardii is a probiotic yeast, not a bacterium. This is the most important practical difference between S. boulardii and the more familiar bacterial probiotics such as Lactobacillus and Bifidobacterium. Because it is a yeast, it is not inactivated by antibacterial antibiotics, which makes it particularly useful during antibiotic exposure, the context in which its evidence base is strongest.

The specific preparation that carries the main clinical evidence base is Saccharomyces boulardii CNCM I-745. The strain or preparation designation matters here just as much as it does for bacterial probiotics. Products labelled simply as Saccharomyces boulardii without further characterisation may not be equivalent to the preparations used in the key trials.

Its biological properties include resistance to gastric acid, relative stability during antibiotic treatment, and several plausible mechanisms relevant to diarrhoeal disease, including interference with pathogen and toxin effects, support of epithelial barrier function, and modulation of luminal immune responses. These properties support its clinical plausibility, but mechanism does not substitute for trial evidence. The reason S. boulardii is clinically relevant is that it has both.

What the evidence shows

Antibiotic-associated diarrhoea prevention. This is the best-supported application for S. boulardii and the reason for the Strong primary rating. Multiple meta-analyses show a clinically meaningful reduction in antibiotic-associated diarrhoea risk in adults and children. The practical advantage of S. boulardii in this setting is straightforward: because it is a yeast, it can be given concurrently with antibiotics without being inactivated by them.

Acute gastroenteritis and acute infectious diarrhoea in children. S. boulardii reduces diarrhoea duration by approximately one day on average in paediatric acute gastroenteritis. This is a real effect, but the evidence quality is lower than for antibiotic-associated diarrhoea prevention. The most recent systematic review judged the certainty of evidence low to very low, and guideline recommendations are correspondingly weak rather than strong.

Adjunctive use during H. pylori eradication therapy. S. boulardii reduces eradication-therapy adverse effects, particularly diarrhoea, and may modestly improve eradication rates when added to standard treatment. The adverse-effect reduction signal is more clinically secure than the eradication-rate improvement. This is an adjunctive use case, not evidence for S. boulardii as a primary anti-H. pylori treatment.

C. difficile prevention. This is more complicated than many summaries suggest. Older trials and broader probiotic meta-analyses supported a possible role for S. boulardii in recurrent or high-risk C. difficile settings, but more recent strain-specific meta-analysis has not confirmed a clear preventive benefit. The clinical evidence here is mixed and weaker than is often implied in marketing.

IBS and general digestive wellness. Evidence for IBS symptom relief is limited and inconsistent. S. boulardii should not be presented as a well-established IBS probiotic. General wellness claims, immune support claims, and broad “microbiome balance” claims all go substantially beyond the current clinical evidence.

Practical considerations

S. boulardii is typically used at doses of 250mg twice daily to 500mg twice daily, depending on formulation and indication. For antibiotic-associated diarrhoea prevention, the relevant practical point is timing, it should be started with the antibiotic course rather than after diarrhoea has already developed if the goal is prevention.

Because it is a yeast, ambient stability is often better than for some bacterial probiotics, but this is formulation-dependent and should not be assumed. Expiry date, product quality, and strain verification still matter. As with all probiotics, a labelled organism is not by itself evidence of efficacy, the question is whether the specific preparation matches the studied one.

Safety

S. boulardii is generally well tolerated in healthy adults and children. Transient bloating, constipation, thirst, and mild GI discomfort are the most commonly reported adverse effects. In healthy populations, serious adverse events are rare.

The key safety caveat is not theoretical. Fungaemia associated with S. boulardii has been documented, particularly in immunocompromised patients, critically ill individuals, and those with central venous catheters. This is uncommon, but it is real and clinically relevant. That risk is the main reason S. boulardii should not be used casually in high-risk inpatient settings without medical supervision.

What can reasonably be concluded

Saccharomyces boulardii CNCM I-745 is one of the most evidence-supported individual probiotic organisms for a specific clinical indication: prevention of antibiotic-associated diarrhoea. That indication justifies a Strong rating.

Evidence for acute gastroenteritis in children and adjunctive use during H. pylori eradication therapy is meaningful but weaker, and should be presented as Moderate rather than strong. Evidence for recurrent C. difficile prevention is mixed and currently too inconsistent for a confident recommendation. IBS and general immune or wellness claims are not well supported.

The key practical point is that S. boulardii is not a general “good gut health” product with broad transferable effects. It is a specific probiotic yeast with a narrow set of indications that are genuinely supported by evidence. Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.